KAL
15.1.2020 17:02:12 CET | Business Wire | Press release
In a world first, KAL ATM Software and Česká spořitelna have rolled out the first ATM running Windows 10 on a Linux Hypervisor.
KAL’s new Kalignite Hypervisor solution, in partnership with Red Hat, is a game-changing solution that allows banks to break free from enforced, costly and disruptive ATM hardware upgrades.
It uses OS-Virtualization technology to solve the long-standing problem of enforced ATM hardware upgrades and decouples the ATM PC-core from the ATM operating system so that software drivers that are unsupported under new Windows operating system versions can be supported by the Linux drivers instead.
Česká spořitelna’s ATM Software Innovation product owner, Jakub Otáhal, explains that the end of support for Windows 7, and the accompanying expense and complexity of upgrading ATM hardware and software to Windows 10, prompted the decision to install Kalignite Hypervisor in a pilot production environment.
He said: “KAL’s new solution gives Česká spořitelna control over when to carry out hardware upgrades. This means we can cut costs by keeping to our 10-11 year renewal recycle, rather than being forced to comply with the hardware lifetime. Very importantly, Kalignite Hypervisor also enables us to keep our software right up to date.”
KAL CEO Aravinda Korala added: “We are delighted that Česká spořitelna decided to partner with us to achieve this impressive world first. Kalignite Hypervisor enables Česká spořitelna to stay completely up to date and run the latest versions of all software on their ATMs. Not only does this technology help with the Windows 10 migration, it also allows Česká spořitelna to migrate to new Windows LTSC and SAC upgrades without requiring hardware changes.”
About Česká spořitelna
Česká spořitelna is the largest bank in the Czech Republic with more than four million clients and the most extensive branch and ATM networks in the country. It provides services for individuals, small and medium-sized enterprises, towns and municipalities, and finances large corporations.
Česká spořitelna is proud of its long tradition – it was established in 1825 as the first savings bank in the Czech Republic – but it is equally proud of its role as an innovator. Many of its products and services are leaders in the Czech market. The bank has been a member of the Erste Group since 2000.
For more information, visit www.csas.cz/en/about-us/who-we-are
About KAL
KAL is a world-leading ATM software company and the preferred supplier to mega-banks such as Citibank, UniCredit, ING and China Construction Bank.
KAL’s software gives banks full control of their ATM network, reducing costs, meeting all security needs and improving competitiveness. It is installed and supported in more than 80 countries.
For more information, visit www.kal.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005065/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom